Pharma Mar SA (PHM):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9808)
◆英語タイトル:Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9808
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA (PHM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Merger 14
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Licensing Agreements 15
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Equity Offering 28
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA – Key Competitors 29
Pharma Mar SA – Key Employees 30
Pharma Mar SA – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Oct 30, 2018: PharmaMar reports net profit of €5 million at the end of the third quarter of 2018 33
Jul 26, 2018: PharmaMar group obtained a net profit of €3 million in the first half of 2018 34
Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35
Feb 28, 2018: PharmaMar group announces 2017 earnings results 36
Oct 24, 2017: Pharma Mar group revenues totalled €140 million in the first nine months of the year 37
Jul 26, 2017: Pharma Mar group reports first half financial results 38
Apr 27, 2017: PharmaMar Group reports €45.5 million in revenues (+8%) 39
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 40
Corporate Communications 42
Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development 42
Government and Public Interest 43
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 43
Product News 45
06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 45
04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46
04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 47
Clinical Trials 48
Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound –PM14- in Patients with Solid Tumors 48
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 49
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 50
Other Significant Developments 51
Jul 30, 2018: Immedica – a platform for pan-European niche specialty pharma launch, commercialization and distribution services 51
Jun 28, 2018: PharmaMar’s 2017 Group Annual General Shareholder’s’ meeting 52
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA, Key Competitors 29
Pharma Mar SA, Key Employees 30
Pharma Mar SA, Subsidiaries 31

List of Figures
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Pharma Mar SA (PHM):製薬・医療:M&Aディール及び事業提携情報(Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆